An Investigational Immunotherapy Study of Nivolumab With Standard of Care Therapy vs Standard of Care Therapy for First-Line Treatment of Colorectal Cancer That Has Spread

Local Institution - 0046, New York

Local Institution - 0031, Johnson City

Local Institution - 0024, Pittsburgh

Local Institution - 0005, Philadelphia

Local Institution - 0021, Bethesda

Local Institution - 0025, Richmond

Local Institution - 0028, Roanoke

Local Institution - 0042, Madrid

Local Institution - 0041, Majadahonda - Madrid

Levine Cancer Institute, Charlotte

Local Institution - 0039, Miami

Local Institution - 0047, St. Petersburg

Local Institution - 0019, Nashville

Erlanger Oncology & Hematology - Univ. of TN, Chattanooga

Local Institution - 0044, Indianapolis

Local Institution - 0006, Madison

Local Institution - 0035, Minneapolis

Local Institution - 0002, Rochester

Local Institution - 0023, Sioux Falls

Local Institution - 0033, Arlington Heights

Local Institution - 0032, Papillion

Local Institution - 0034, Dallas

Local Institution - 0036, Tyler

Local Institution - 0026, Bedford

Local Institution - 0037, Fort Worth

Local Institution - 0040, San Antonio

Local Institution - 0010, Aurora

Local Institution - 0027, Denver

Local Institution - 0029, Henderson

Local Institution - 0004, Los Angeles

Local Institution - 0038, Portland

Local Institution - 0051, Kashiwa-shi

Local Institution - 0050, Sunto-gun

Local Institution - 0055, Nagoya

Uab Comprehensive Cancer Center, Birmingham

Local Institution - 0020, New Haven

Local Institution - 0003, Boston

Local Institution - 0049, Boston

Local Institution - 0052, Boston

Local Institution - 0053, Boston

Local Institution - 0017, Edmonton

Local Institution - 0015, Ottawa

Local Institution - 0014, Toronto

Local Institution - 0048, Montreal

Local Institution - 0012, Québec

Local Institution - 0013, Sherbrooke

Local Institution - 0016, Trois-Rivières

Local Institution - 0009, San Juan

Local Institution - 0043, Barcelona